Journal
BIOORGANIC & MEDICINAL CHEMISTRY
Volume 26, Issue 3, Pages 590-602Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2017.12.020
Keywords
Casein kinase 1 delta and epsilon; Kinase; Inhibitor; Structure-activity relationship; Breast cancer
Funding
- NIH NCI [R01CA175094]
- NIH NCI NRSA [F32CA200105]
Ask authors/readers for more resources
Casein kinase 1 delta/epsilon have been identified as promising therapeutic target for oncology application, including breast and brain cancer. Here, we described our continued efforts in optimization of a lead series of purine scaffold inhibitors that led to identification of two new CK1 delta/epsilon inhibitors 17 and 28 displaying low nanomolar values in antiproliferative assays against the human MDA-MB-231 triple negative breast cancer cell line and have physical, in vitro and in vivo pharmacokinetic properties suitable for use in proof of principle animal xenograft studies against human cancers. (C) 2017 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available